Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Express Scripts
Boehringer Ingelheim
Medtronic
Fuji
Moodys
Accenture
AstraZeneca
US Army
Covington

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062638

« Back to Dashboard
NDA 062638 describes ERYTHROCIN, which is a drug marketed by Hospira, Abbott, and Arbor Pharms Llc, and is included in five NDAs. It is available from one supplier. Additional details are available on the ERYTHROCIN profile page.

The generic ingredient in ERYTHROCIN is erythromycin stearate. There are ninety-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the erythromycin stearate profile page.

Summary for NDA: 062638

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 062638

Ingredient-typeMacrolides
Physiological EffectDecreased Sebaceous Gland Activity

Suppliers and Packaging for NDA: 062638

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ERYTHROCIN
erythromycin lactobionate
INJECTABLE;INJECTION 062638 ANDA Hospira, Inc. 0409-6476 0409-6476-44 10 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-6476-44) > 100 mL in 1 VIAL, PATENT DELIVERY SYSTEM

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 500MG BASE/VIAL
Approval Date:Oct 31, 1986TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 1GM BASE/VIAL
Approval Date:Oct 31, 1986TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Dow
Chinese Patent Office
Daiichi Sankyo
Accenture
Covington
Mallinckrodt
Citi
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot